Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsors and Collaborators: |
Celgene Corporation Prologue Research International |
---|---|
Information provided by: | Celgene Corporation |
ClinicalTrials.gov Identifier: | NCT00179660 |
Subjects who qualify will receive lenalidomide daily on days 1-21 of every 28 day cycle. Treatment will continue until for up to 52 weeks or until disease progression, subjects who achieve a CR will receive an additional 2 cycles of treatment prior to discontinuation. Subjects will be followed for progression free survival following discontinuation from the treatment phase
Condition | Intervention | Phase |
---|---|---|
Non-Hodgkins Lymphoma |
Drug: CC-5013 |
Phase II |
Study Type: | Interventional |
Study Design: | Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study |
Official Title: | A Phase II, Multicenter, Single-Arm, Open-Label Study To Evaluate The Safety And Efficacy Of Single-Agent Lenalidomide (Revlimid®, CC-5013) In Subjects With Relapsed Or Refractory Aggressive Non-Hodgkin’s Lymphoma |
Estimated Enrollment: | 40 |
Study Start Date: | June 2005 |
Estimated Study Completion Date: | November 2006 |
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Any of the following laboratory abnormalities:
United States, Arizona | |
Mayo Clinic Scottsdale | |
Scottsdale, Arizona, United States, 85259 | |
United States, California | |
UC David Cancer Center | |
Sacramento, California, United States, 95817 | |
Pacific Coast Hematology/Oncology Medical Group, Onc. | |
Fountain Valley, California, United States, 92708 | |
United States, Florida | |
Sylvester Cancer CenterUniversity Of Miami | |
Miami, Florida, United States, 33136 | |
United States, Minnesota | |
Mayo Clinic | |
Rochester, Minnesota, United States, 55905 | |
United States, Nebraska | |
University of Nebraska | |
Omaha, Nebraska, United States, 68198-6805 | |
United States, New York | |
New York Medical Center, MBCCOP | |
Bronx, New York, United States, 10466 | |
United States, Wisconsin | |
Gunderson Clinic, Ltd | |
La Crosse, Wisconsin, United States, 54601 |
Study ID Numbers: | CC-5013-NHL-002 |
Study First Received: | September 13, 2005 |
Last Updated: | November 29, 2006 |
ClinicalTrials.gov Identifier: | NCT00179660 |
Health Authority: | United States: Food and Drug Administration |
celgene cc-5013 CC5013 |
NHL Non-Hodgkins Lymphoma Revlimid |
Lymphatic Diseases Immunoproliferative Disorders Lenalidomide Lymphoma, small cleaved-cell, diffuse |
Lymphoproliferative Disorders Aggression Lymphoma, Non-Hodgkin Lymphoma |
Neoplasms Neoplasms by Histologic Type Immune System Diseases |
Antineoplastic Agents Therapeutic Uses Pharmacologic Actions |